PTC Therapeutics (PTCT) P/B ratio
The P/B ratio of PTC Therapeutics (PTCT) was 8.4× at the end of fiscal 2020 (December 31, 2020). That is 75.8% higher than the 4.8× of fiscal 2019. Figures as of 18 Nov 2026, 08:20 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/B ratio, fiscal 2020
- 8.4×
- Change on fiscal 2019
- +75.8%
- Highest on record
- 8.4×fiscal 2020
- Lowest on record
- 1.6×fiscal 2013
- Fiscal years on record
- 42013–2020
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
PTC Therapeutics P/B ratio, in more detail
Across the 4 fiscal year-ends on record (2013–2020), the highest was 8.4× in fiscal 2020 and the lowest 1.6× in fiscal 2013.
P/B ratio at each fiscal year-end
PTC Therapeutics P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| 2025 | — | — | $75.96 | -$2.32 | |
| 2024 | — | — | $45.14 | -$14.29 | |
| 2023 | — | — | $27.56 | -$10.94 | |
| 2022 | — | — | $38.17 | -$4.84 | |
| 2021 | — | — | $39.83 | $0.02 | |
| 2020 | 8.4× | 75.8% up | $61.03 | $7.30 | |
| 2019 | 4.8× | — | $48.03 | $10.10 | |
| 2018 | — | — | $34.32 | — | |
| 2017 | — | — | $16.68 | — | |
| 2016 | — | — | $10.91 | — | |
| 2015 | — | — | $32.40 | — | |
| 2014 | 5.5× | 243.4% up | $51.77 | $9.46 | |
| 2013 | 1.6× | — | $16.97 | $10.64 | |
| 2012 | — | — | — | -$161.41 | |
| 2011 | — | — | — | -$35.13 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
P/B ratio at health care companies of similar size
| Company | P/B ratio |
|---|---|
| BillionToOne BLLN | 9.7× |
| Hims & Hers Health HIMS | 7.6× |
| Haemonetics HAE | 6.9× |
| Erasca ERAS | 15.0× |
| Concentra Group Holdings Parent CON | 13.5× |
Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.
PTC Therapeutics, figure by figure
- PTC Therapeutics market cap
- PTC Therapeutics revenue
- PTC Therapeutics earnings
- PTC Therapeutics earnings per share (EPS)
- PTC Therapeutics P/E ratio
- PTC Therapeutics P/S ratio
- PTC Therapeutics free cash flow
- PTC Therapeutics operating margin
- PTC Therapeutics dividend
- PTC Therapeutics shares outstanding
- PTC Therapeutics total debt
- PTC Therapeutics cash on hand
- PTC Therapeutics total assets
- PTC Therapeutics return on equity (ROE)
- PTC Therapeutics return on invested capital (ROIC)
PTC Therapeutics (PTCT) overview: price, valuation and scorecardAll health care companies by market value
PTC Therapeutics P/B ratio: questions and answers
What is PTC Therapeutics's P/B ratio?
The P/B ratio of PTC Therapeutics (PTCT) was 8.4× at the end of fiscal 2020 (December 31, 2020). That is 75.8% higher than the 4.8× of fiscal 2019.
What are the highest and lowest P/B ratio figures on record for PTC Therapeutics?
Across the 4 fiscal year-ends on record (2013–2020), the highest was 8.4× in fiscal 2020 and the lowest 1.6× in fiscal 2013.
How is PTC Therapeutics's P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “PTC Therapeutics (PTCT) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/PTCT/pb-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.